Design and Synthesis of Fibroblast MULTIVALENT Drugs and Imaging Agents

Back to all technologies
Download as PDF
2019-LOW-68745
Researchers at Purdue University have developed two new drugs to treat idiopathic pulmonary fibrosis (IPF). IPF leads to gradual stiffening of the lungs until no gas exchange can occur. There remains an unmet need for treating patients with IPF as current drug candidates including pirfenidone and nintedanib generally exhibit minimal efficacy and may only delay but not prevent disease progression. The new drug candidates created by Purdue researchers target IPF pathologies by delivering therapeutic payloads specifically to two cell types, the infiltrating profibrotic macrophages and the fibrosis-producing myofibroblasts. By targeting the drugs to these two cell types the researchers are able to minimize toxicity to healthy tissues, thereby rendering the drugs much safer than traditional nontargeted therapies.

Advantages:
-Significant improvement in potency
-Can minimize toxicity

Potential Applications:
-Drug discovery
-Treating idiopathic pulmonary fibrosis

Technology Validation: Gaining funding for preclinical trials
Jul 22, 2020
PCT-Patent
WO
(None)
(None)

Nov 11, 2019
Provisional-Patent
United States
(None)
(None)

Oct 4, 2019
Provisional-Patent
United States
(None)
(None)

Jul 22, 2019
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org